Identification | Back Directory | [Name]
4-(BUTYLAMINO)BENZOIC ACID | [CAS]
4740-24-3 | [Synonyms]
NSC44300 NSC 44300 MLS000776796 SMR000413195 STOCK1S-53913 CBDivE_002387 262412_ALDRICH Tetracaine Impurity B LABOTEST-BB LT00000179 Tetracaine EP Impurity B 4-(BUTYLAMINO)BENZOIC ACID 4-n-butylaminobenzoic acid para-Butylaminobenzoic acid Benzoic acid, 4-(butylamino)- Tetracaine Related Compound B 4-(ButylaMino)benzoic acid 97% Tetracaine USP Related Compound B 4-(BUTYLAMINO)BENZOIC ACID USP/EP/BP Tetracaine hydrochloride EP Impurity B Tetracaine Impurity 2(Tetracaine EP Impurity B) Tetracaine Related Compound B (4-(Butylamino)benzoic acid) (1650017) 4-n-butylamino benzoic acidQ: What is
4-n-butylamino benzoic acid Q: What is the CAS Number of
4-n-butylamino benzoic acid | [Molecular Formula]
C11H15NO2 | [MDL Number]
MFCD00002536 | [MOL File]
4740-24-3.mol | [Molecular Weight]
193.24 |
Chemical Properties | Back Directory | [Melting point ]
149-151 °C(lit.) | [Boiling point ]
353.5±25.0 °C(Predicted) | [density ]
1.130±0.06 g/cm3(Predicted) | [storage temp. ]
Keep in dark place,Inert atmosphere,Room temperature | [solubility ]
Chloroform (Slightly), Methanol (Slightly) | [form ]
Solid | [pka]
4.77±0.10(Predicted) | [color ]
Off-White to Pale Beige |
Hazard Information | Back Directory | [Uses]
4-(Butylamino)benzoic Acid is an intermediate used to synthesize 5-nitrothiophene derivatives with antimicrobial activity against multidrug-resistant Staphylococcus aureus. | [Definition]
ChEBI: 4-Aminobenzoic acid in which one of the hydrogens attached to the nitrogen is substituted by a butyl group. | [reaction suitability]
reaction type: solution phase peptide synthesis | [Synthesis]
4-(Butylamino)benzoic acid (compound 3) was synthesized as follows: compound 2 (about 3 mmol) was dissolved in 15 mL of methanol, R-methylpyridine-borane (1.1 eq.) and n-butyraldehyde (1.1 eq.) were added. The reaction mixture was sealed with a vented pin plug and the reaction was stirred at room temperature for 16-24 hours. After completion of the reaction, the solvent was removed by distillation under reduced pressure. To the residue, 10 mL of 1 M HCl solution was added and stirring was continued for 30 minutes at room temperature. Subsequently, the pH was adjusted to neutral with NaHCO3 solution and the target product was extracted with ethyl acetate (2 x 60 mL). The organic layers were combined, washed once with brine (45 mL), dried over anhydrous magnesium sulfate, filtered and concentrated under reduced pressure. Finally, the target product compound 3 was purified by column chromatography (eluent: hexane solution of 30% ethyl acetate) to give the target product compound 3 in white powder form in 88% yield. The structure of the product was confirmed by 1H NMR (500 MHz, CD3OD) and 13C NMR (125 MHz, CD3OD). | [References]
[1] Journal of Organic Chemistry, 2007, vol. 72, # 25, p. 9815 - 9817 [2] Journal of Medicinal Chemistry, 2011, vol. 54, # 13, p. 4904 - 4912 [3] Patent: US2014/18422, 2014, A1. Location in patent: Paragraph 0098 |
|
|